12:00 AM
 | 
Jan 07, 2013
 |  BC Week In Review  |  Company News  |  Deals

Repligen, Pfizer deal

Repligen granted Pfizer exclusive, worldwide rights to develop and commercialize Repligen's spinal muscular atrophy (SMA) program, which includes lead candidate RG3039 and undisclosed backup SMA compounds. Repligen will receive $5 million up front and is eligible...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >